

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of identifying an attenuated respiratory syncytial virus (RSV) strain that produces high yields of RSV surface glycoprotein F when compared with the parent A2 strain, which method comprises:
 providing a eukaryotic cell culture;
 infecting the eukaryotic cell culture with a live, attenuated RSV strain at 30°C;
 and
 determining the glycoprotein F concentration in the harvest of the culture, wherein at least a five-fold increase in glycoprotein F concentration is produced when the attenuated RSV strain is grown in the cell culture at 30°C is an indication that the attenuated RSV strain produces high yields of RSV F glycoproteins when compared with the parent A2 strain grown at 37°C.
2. (Original) The method of claim 1, wherein the identified attenuated RSV strain is the RSV mutant strain *cpts-248/404*.
3. (Original) The method of claim 1, wherein the eukaryotic cell culture is a VERO, MRC-5, FRhL, CEF or PER.C6 cell culture.
4. (Withdrawn) A process for producing purified RSV F protein comprising:
 growing eukaryotic cells infected with the RSV mutant strain *cpts-248/404* in a cultured medium at 30°C;
 solubilizing the F protein from the virus-infected cell membrane; and
 isolating and purifying the solubilized F protein.
5. (Withdrawn) The process of claim 4, wherein the isolating and purifying is effected by loading the solubilized F protein onto an ion-exchange matrix, and eluting the F protein from the ion-exchange matrix.

6. (Withdrawn) The process of claim 4, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
7. (Withdrawn) A process for producing an immunogenic composition for protecting against disease caused by RSV, wherein said process comprises producing an RSV F protein by a process according to claim 4 and bringing an effective amount of said F protein into combination or association with a physiologically acceptable carrier.
8. (Withdrawn) Purified RSV F protein produced by the process of claim 4.
9. (Withdrawn) Respiratory syncytial virus (RSV) fusion (F) protein, produced by a process comprising:
growing RSV mutant strain cpts-248/404 on eukaryotic cells in a cultured medium at 30°C;
solubilizing the F protein from the separated virus; and
isolating and purifying the solubilized F protein by ion-exchange chromatography.
10. (Withdrawn) The isolated RSV F protein of claim 9, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
11. (Withdrawn) A process for producing purified RSV G protein comprising:
growing eukaryotic cells infected with the RSV mutant strain cpts-248/404 in a cultured medium at 30°C;
solubilizing the G protein from the virus-infected cell membrane; and
isolating and purifying the solubilized G protein.
12. (Withdrawn) The process of claim 10, wherein the isolating and purifying is effected by loading the solubilized G protein onto ion-exchange and affinity matrixes, and eluting the G protein from the matrixes.
13. (Withdrawn) The process of claim 10, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.

14. (Withdrawn) A process for producing an immunogenic composition for protecting against disease caused by RSV, wherein said process comprises producing an RSV G protein by a process according to claim 11 and bringing an effective amount of said G protein into combination or association with a physiologically acceptable carrier.
15. (Withdrawn) Purified RSV G protein produced by the process of claim 11.
16. (Withdrawn) Respiratory syncytial virus (RSV) attachment (G) protein, produced by a process comprising:
growing RSV mutant strain cpts-248/404 on eukaryotic cells in a cultured medium at 30°C;
solubilizing the G protein from the separated virus; and
isolating and purifying the solubilized G protein by ion-exchange and affinity chromatography.
17. (Withdrawn) The isolated RSV G protein of claim 16, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
18. (Canceled)